Albers Jeffrey W. sold $522K of SYRE
Albers Jeffrey W. sold 5,000 shares of Spyre Therapeutics, Inc. (SYRE) at $104.47 ($0.52M total) on 2026-08-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size, price ($104.47), and post-transaction holdings (0 shares) by a director under a 10b5-1 plan.
Market read
Traders may briefly reassess sentiment around SYRE due to a director sale, but the 10b5-1 structure reduces interpretive value.
What to watch
The article does not state whether other insiders sold, whether there were concurrent buys, or any changes in company fundamentals, limiting signal strength.
Background
This is an SEC Form 4 insider transaction disclosure for Spyre Therapeutics, Inc. (SYRE).
Ticker impact
Spyre Therapeutics director Jeffrey W. Albers sold 5,000 shares in an open-market transaction at $104.47, leaving 0 shares.
Likely limited immediate impact; any reaction would be sentiment-driven rather than fundamental.
Form 4 shows a pre-arranged 10b5-1 sale and the insider ends with 0 shares, but the article provides no new company fundamentals or guidance.
Market effects
No sector-level implications; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.
Key entities
- issuerSpyre Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderJeffrey W. Albers
Director who sold 5,000 shares in an open-market transaction under a 10b5-1 plan.
